24.Lai CL, Lin RT, Liou LM, Liu CK. The role of event-related potentials in cognitive decline in Alzheimer's disease. Clin Neurophysiol. 2010;121:194-199.
25.Golob EJ, Ringman JM, Irimajiri R, et al. Cortical event-related potentials in preclinical familial Alzheimer disease. Neurology. 2009;73:1649-1655.
26.Mattsson N, Rosen E, Hansson O, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 2012;78:468-476.
27.Wright DW, Nevarez H, Kilgo P, et al. A novel technology to screen for cognitive impairment in the elderly. American Journal of Alzheimer’s Disease and Other Dementias. 2011;26:484-491.
28.Sachdev PS, Lipnicki DM, Crawford J, et al. Risk profiles of subtypes of mild cognitive impairment: the Sydney Memory and Aging Study. J Am Geriatr Soc. 2012;60:24-33.
29.Jacobs HI, Van Boxtel MP, Heinecke A, et al. Functional integration of parietal lobe activity in early Alzheimer disease. Neurology. 2012;78:352-336.
30.Buchman AS, Bennett DA. Amyloid pathology in persons with “normal” cognition. Neurology. 2012;78: 228-229.
31.Bis JC, Decarli C, Smith AV, et al. Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nat Genet. 2012;44:545-551.
32.De Marchis GM, Foderaro G, Jemora J, et al. Mild cognitive impairment in medical inpatients: the mini-mental state examination is a promising screening tool. Dement Geriatr Cogn Disord. 2010;29:259-264.
33.Scazufca M, Almeida OP, Vallada HP, Tasse WA, Menezes PR. Limitations of the Mini-Mental State Examination for screening dementia in a community with low socioeconomic status: results from the Sao Paulo Ageing & Health Study. Eur Arch Psychiatry Clin Neurosci. 2009;259:8-15.
34.Gualtieri CT, Johnson LG. Age-related cognitive decline in patients with mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:962-967.
35.Nieuwenhuis-Mark RE. The death knoll for the MMSE: has it outlived its purpose? J Geriatr Psychiatry Neurol. 2010;23:151-157.
36.McCarten JR, Rottunda SJ, Kuskowski MA. Change in the mini-mental state exam in Alzheimer's disease over 2 years: the experience of a dementia clinic. J Alzheimers Dis. 2004;6:11-15.
37.Tierney MC, Szalai JP, Dunn E, Geslani D, McDowell I. Prediction of probable Alzheimer disease in patients with symptoms suggestive of memory impairment. Value of the Mini-Mental State Examination. Arch Fam Med. 2000;9:527-532.
38.Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 199240: 922-35.
39.Ashford JW, Kolm P, Colliver JA, Bekian C, Hsu LN. Alzheimer patient evaluation and the mini-mental state: item characteristic curve analysis. J Gerontol. 1989;44:139-146.
40.Vemuri P, Weigand SD, Knopman DS, et al. Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. Neuroimage. 2010;54:985-991.
41.Borroni B, Anchisi D, Paghera B, et al. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging. 2006;27:24-31.
42.Hedman AM, van Haren NEM, Schnack HG, Kahn RS, Hulshoff Pol HE. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp. 2012;33:1987-2002.
43.Talan, J. Largest imaging study identifies genes that affect brain size, hippocampal volume: links found to intelligence and memory. Neurology Today. 2012;12:1.
44.Rodrigue KM, Kennedy KM, Devous MD, et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387-395.
45.Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78:709-719.
46.Dickerson BC, Wolk DA. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology. 2012;78:84-90.
47.Smith EE, Salat DH, Jeng J, et al. Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology. 2011;76:1492-1499.
48.Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63:665-672.
49.Ridgway GR, Lehmann M, Barnes J, et al. Early-onset Alzheimer disease clinical variants: Multivariate analyses of cortical thickness. Neurology. 2012;79:80-84.
50.Hathaway A. Women, Estrogen, Cognition, and Alzheimer’s disease. Townsend Letter. 2012:64.
51.Ahiskali M, Green D, Kounios J, Clark CM, Polikar R. ERP based decision fusion for AD diagnosis across cohorts. Conf Proc IEEE Eng Med Biol Soc. 2009:2494-2497.
52.Lockwood AH, Wack DS, Benedict RHB, et al. Multi-site phasic neural activity mediates the execution of an auditory continuous performance task: a PET and electrophysiological study. Journal of Neuroimaging. 2008;18:364-374.
53.Perrin, F, Maquet P, Peigneux P, et al. Neural mechanisms involved in the detection of our first name: a combined ERPs and PET study. Neuropsychologia. 2005;43:12-19.
54.Reinsel RA, Veselis RA, Feshchenko A, et al. Target detection and the prefrontal cortex: a PET scan study of the P300 event-related potential. Annals New York Academy of Sciences. 1995;l769:393-397.
55.Marsh JT, Schubarth G, Brown WS, et al. PET and P300 relationships in early Alzheimer’s Disease. Neurobiology of Aging. 1990;11:471-476.
56.Correa F. AD, Dementia cost $200 billion. Clinical Psychiatry News. 2012;40:33.
ABOUT THE AUTHOR
Primary author Eric R. Braverman, M.D. is the Medical Director of PATH (The Place for Achieving Total Health) Medical, in New York City, NY, a full-service integrative medical practice.
Chapter 5
Hormonal Correlations in Female Menopausal Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bioidentical Replacement Therapy (MHRT)
Eric R Braverman. M.D., Kenneth Perrine, Uma J Damle, Stella Savarimuth, Swetha Yeldandi, Mallory Kerner, Kristina Dushaj, Elizabeth Mo, Pooja Reddy, Pavan Reddy, Mona Li, Danielle Stratton, Kenneth Blum, Ph.D.
1 Department of Neurological Surgery, Weill Cornell College of Medicine, New York, USA
2 Department of Clinical Neurology, PATH Foundation NY, New York, USA
3 Department of Psychiatry, University of Florida, College of Medicine and McKnight Brain Institute, Gainesville, Florida, USA
ABSTRACT
Menopausal women develop multiple hormonal alterations. 74 females were included (mean age=60.23, SD=9.21). A medical evaluation was completed with hormone screening using a number of statistical analyses such as Pearson Product Moment; One way ANOVA and Regression analysis along with a Bonferroni significance correction p<.004. Of 120 correlations performed, significant hormone/domain correlations were as follows: DHEA/genitourinary (r=.30, p<.05); FSH/pulmonary (r=-.29, p<.05); pregnenolone/genitourinary (r=.40, p<.006) /immunological (r=.38, p<.008); testosterone/total endorsed symptoms (r=-0.34, p<.016); TSH/pulmonary (r=-.33, p<.03) /gynecological (r=.30, p<.05). estrone/musculoskeletal (r=-0.43, p<.012). After a Bonferroni correction (experiment-wise p<.00045) for statistical significance, no hormones remained significant. In the follow–up phase FSH/neuropsychiatric (r=.56, p<.05) and /musculoskeletal (r=.67, p<.013); DHEA/immunological (r=.64, p<.04); LH/musculoskeletal (r=.59, p<.34); free testosterone/neuropsychiatric (r=.64, p<.019), /musculoskeletal (r=.68, p<.01), and /dermatologic (r=.57, p<.04); total testosterone/immunological (r=.63, p<.028); TSH/endocrinological